cfDNA sequencing reveals response heterogeneity to first-line camrelizumab plus chemotherapy in esophageal squamous cell carcinoma

AiRuiKa (camrelizumab) - Elevar Therapeutics

http://www.ncbi.nlm.nih.gov/pubmed/42331551

B Yang; F Su; G H Song; H Wang; J Zhao; M Liu; W Q Hu; W X Fan; X L Zhang; Y J Gao; Y X Zhang; Y Y Du; Z D Guo

Jun 23, 2026